The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective

The emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit from immunotherapy in clinical practice. In addit...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Shuai, Wang, Hanyu, Tian, Haixia, Xu, Zhicheng, Wu, Min, Hua, Dong, Li, Chengming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518408/
https://www.ncbi.nlm.nih.gov/pubmed/37753089
http://dx.doi.org/10.3389/fimmu.2023.1249980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518408/
https://www.ncbi.nlm.nih.gov/pubmed/37753089
http://dx.doi.org/10.3389/fimmu.2023.1249980

Ejemplares similares